Hepatocellular Carcinoma – Epidemiology – Europe

Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of hepatocellular carcinoma for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

Clarivate Epidemiology’s hepatocellular carcinoma forecast will answer the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with hepatocellular carcinoma per year?
• Of all people diagnosed with hepatocellular carcinoma, how many in each country in the developed world are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of hepatocellular carcinoma over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Clarivate Epidemiology forecasts the following hepatocellular carcinoma patient populations:

• Diagnosed incident cases
• Diagnosed incident cases by stage distribution
• Diagnosed prevalent cases
• Diagnosed prevalent cases by metastasis status
• Diagnosed advanced first-line drug-treatable population
• Diagnosed advanced first-line drug-treatable population by treatment
• Diagnosed advanced second-line drug-treatable population
• Diagnosed advanced second-line drug-treatable population by treatment
• Diagnosed intermediate drug-treatable population
• Diagnosed intermediate drug-treatable population by treatment
• Diagnosed early drug-treatable population
• Diagnosed early drug-treatable population by treatment
• … and many more (details available on request).

Note: Coverage may vary by country.